Samsung Bioepis Selects Two Companies for Seoul Biohub Open Innovation Program

Frazier Therapeutics and BioInsight Join Program
Support for TPD and AI-based Drug Development Technologies
Collaboration Opportunities in Joint Research and Technology Transfer

Samsung Bioepis announced on the 22nd that it has selected two participating companies for the '2026 Seoul Biohub-Samsung Bioepis Open Innovation Program,' which it operates in partnership with Seoul Biohub, and held an agreement ceremony.

Stakeholders are taking a commemorative photo at the 2026 Seoul Biohub-Samsung Bioepis Open Innovation Program Agreement Ceremony. Samsung Bioepis

The selected companies are Frazier Therapeutics, which owns next-generation targeted protein degradation (TPD) platform technology, and BioInsight, which develops an AI-based chemoproteomics platform technology.

This program was established to promote collaboration between domestic biotech startups and global bio companies, as well as to increase the commercialization potential of next-generation bio technologies. Samsung Bioepis will provide the selected companies with support such as technology advancement, mentoring, and commercialization consulting. After the program ends, the company will consider further collaborations, including joint research, technology transfer, joint commercialization, and strategic investments, following a final evaluation.

Frazier Therapeutics is developing a next-generation TPD platform that removes disease-causing proteins by utilizing intracellular protein degradation systems. BioInsight possesses a chemoproteomics platform that utilizes mass spectrometry and artificial intelligence (AI) to analyze drug-protein interactions and discover new drug targets.

Kim Kyung-Ah, CEO of Samsung Bioepis, stated, "Through this program, we will discover next-generation bio technologies and expand our partnership base with promising biotech companies," and added, "We will also strive to contribute to the growth of the domestic bio ecosystem."

Previously, Samsung Bioepis also signed a memorandum of understanding (MOU) for open innovation collaboration with Atlatl Innovation Center, a Chinese biotech incubation institute, further expanding partnerships to secure next-generation technologies.

This content was produced with the assistance of AI translation services.